MedTrace Logo

Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.

NCT04688034 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-10-21

No results posted yet for this study

Summary

To evaluate the safety and tolerability of OP-724 in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia.

Conditions

Interventions

DRUG

OP-724

Twice a week for 4 hours continuous intravenous administration of OP-724.

Sponsors & Collaborators

  • Japan Agency for Medical Research and Development

    collaborator OTHER_GOV

  • Ohara Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Kiminori Kimura, MD

    lead OTHER

Principal Investigators

  • Kiminori Kimura, MD · Tokyo Metropolitan Komagome Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2022-07-05
Completion
2022-07-05

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04688034 on ClinicalTrials.gov